A Phase 2a, Open-label, Dose Finding Study to Determine the Safety and Tolerability of SOTATERCEPT (ACE-011) in Adults With Beta-Thalassemia

Trial Profile

A Phase 2a, Open-label, Dose Finding Study to Determine the Safety and Tolerability of SOTATERCEPT (ACE-011) in Adults With Beta-Thalassemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Sotatercept (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 19 Jan 2017 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
    • 01 Apr 2016 Trial design has been changed from single group assignment to parallel assignment.
    • 18 Aug 2015 Planned End Date changed from 1 Apr 2016 to 1 Nov 2019 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top